Temsirolimus (Torisel) For Advanced Kidney Cancer
The Food and Drug Administration (FDA) has approved temsirolimus (Torisel, Wyeth) for the treatment of advanced kidney cancer.
In a clinical trial of 626 patients, one group received the study drug alone, another received a comparator agent (interferon alfa), and the third group received a combination of the two. The temsirolimus-alone group showed a significant improvement in overall survival.
evista drug
Temsirolimus blocks a key protein that regulates cell proliferation. It also blocks angiogenesis, which creates a blood supply to tumors to maintain their growth.
For more details on temsirolimus, please see this month’s Pharmaceutical Approval Update column, page 377.
